Patents by Inventor Adam Reid ROOT

Adam Reid ROOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)
    Publication number: 20240034780
    Abstract: The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.
    Type: Application
    Filed: July 21, 2023
    Publication date: February 1, 2024
    Inventors: Antonios O. Aliprantis, Zachary Kohl Costello, Anthony John Coyle, Kristen Park Hopson, Ryan Terrell Phennicie, Alexis Hiram Ramos, Adam Reid Root, Lana Dinic, Karin Alma Frieda Reif
  • ANTIBODIES SPECIFIC FOR GUCY2C AND USES THEREOF
    Publication number: 20230340151
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: October 26, 2023
    Applicant: PFIZER INC.
    Inventors: Chew Shun CHANG, Gurkan GUNTAS, Madan KATRAGADDA, Divya MATHUR, Adam Reid ROOT, Lidia MOSYAK, Edward Roland LAVALLIE
  • ANTI-GUCY2C ANTIBODIES AND USES THEREOF
    Publication number: 20230146072
    Abstract: The present invention is directed to antibodies that specifically bind to GUCY2c and methods of using such antibodies in the diagnosis and/or treatment of cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: May 11, 2023
    Applicant: PFIZER INC.
    Inventors: Chew Shun CHANG, Divya MATHUR, Adam Reid ROOT
  • Antibodies specific for GUCY2c and uses thereof
    Patent number: 11525010
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: December 13, 2022
    Assignee: PFIZER INC.
    Inventors: Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland LaVallie
  • ANTIBODIES SPECIFIC FOR GUCY2C AND USES THEREOF
    Publication number: 20200010566
    Abstract: The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 9, 2020
    Applicant: Pfizer Inc.
    Inventors: Chew Shun Chang, Gurkan Guntas, Madan Katragadda, Divya Mathur, Adam Reid Root, Lidia Mosyak, Edward Roland LaVallie
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20180155452
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 7, 2018
    Applicant: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Bispecific heterodimeric diabodies and uses thereof
    Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20160002357
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: June 26, 2015
    Publication date: January 7, 2016
    Applicant: PFIZER INC.
    Inventors: Chad Michael MAY, Adam Reid ROOT, William A. BRADY, Lioudmila Gennadievna TCHISTIAKOVA, Lidia MOSYAK, Laird BLOOM, Paul A. MOORE, Leslie S. JOHNSON